Australian Drug Industry Lays Out Wishlist As Elections Near
Executive Summary
With the government and opposition parties in Australia in full pre-election promise mode, the pharmaceutical industry has called on the future government to guarantee the sustainability of the drug reimbursement system, extend the data exclusivity period and review the National Medicines Policy on access to new drugs.
You may also be interested in...
Australian Research Community Calls For Clinical Trial Harmonization
Complex and divergent clinical trial regulations across Australia have caused leading scientists and clinicians in Australia to press for urgent efforts to harmonize the requirements.
Innovative Cancer Drugs Get Funding In Australian Govt’s Pre-Election Budget
This week's budget in Australia includes extra funding for the reimbursement of some key new cancer drugs under the Pharmaceutical Benefits Scheme, as well as more money for clinical trials of drugs for rare diseases.
Stability At Last For Drug Innovators And Pricing In Australia
The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.